Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxae100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Goran Stegnjaić und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Institute for Biological Research 'Siniša Stanković' - National Institute of Republic of Serbia, University of Belgrade, Be…. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Encephalomyelitis, Autoimmune, Experimental, Carbon Monoxide, Immunomodulating Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministry of Science, Technological Development, and Innovations, Republic of Serbia, SATT.
Abstract (Originalsprache)
HYCOs are hybrid molecules consisting of activators of the transcription factor Nrf2 conjugated to carbon monoxide (CO)-releasing moieties. These ‘dual action’ compounds (HYCOs) have been designed to mimic the activity of heme oxygenase-1 (HO-1), a stress inducible cytoprotective enzyme that degrades heme to CO which expression is regulated by Nrf2. HYCOs have recently shown efficacy in ameliorating experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. However, the mechanism(s) of action of HYCOs still remains to be fully investigated. Here, we assessed the effects of HYCO-3, a prototype of these hybrids, on myeloid-derived cells, microglial cells and T lymphocytes obtained from EAE-immunized mice. HYCO-3 exerted immunomodulatory effects on all the examined cell populations by inhibiting the generation of pro-inflammatory cytokines and nitric oxide, and downregulating antigen-presenting capacity of these cells. The observed effects support the view that HYCOs are promising candidates to be developed for the treatment of autoimmune and chronic inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Institute for Biological Research 'Siniša Stanković' - National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia.
- Faculty of Health, University Paris Est-Créteil, INSERM, IMRB, Paris, France.
ORCID-Profile: Đorđe Miljković
Förderung
- Ministry of Science, Technological Development, and Innovations, Republic of Serbia
- SATT
Zitieren
APA
Stegnjaić, G., Nikolovski, N., Stanisavljević, S., Lazarević, M., Momčilović, M., Foresti, R., Motterlini, R., & Miljković, Đ. (2025). Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae100
Vancouver
Stegnjaić G, Nikolovski N, Stanisavljević S, Lazarević M, Momčilović M, Foresti R, et al. Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxae100
BibTeX
@article{Stegnjai2025,
author = {Stegnjaić, Goran and Nikolovski, Neda and Stanisavljević, Suzana and Lazarević, Milica and Momčilović, Miljana and Foresti, Roberta and Motterlini, Roberto and Miljković, Đorđe},
title = {Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxae100}
}
EUVIMED